Latest news and press releases about Aura Biosciences, Inc. (AURA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology.
Price
| Price | $6.73 |
| Market Cap | $696M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.03 |
| EV / EBITDA | -5.11 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -73.18% |
| Return on Invested Capital | -41.61% |
| Return on Assets | -37.63% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · ANNX · DBVT · DSGN · ENGN · KRRO · LBRX
Explore sector: Healthcare · Biotechnology
More sections of AURA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks